FHLC ETF Analysis: Fidelity Health Care Index | NYSE

Healthcare Equity | NYSE, USA | Market Cap: 3.953m USD | 12M Return: 29.1% | US3160926008 | Charts, Fundamentals & Technical Analysis

Pharmaceuticals, Biotechnology, Medical Devices, Health Insurance
Total Rating 74
Safety 74
Buy Signal 0.56
Healthcare Equity
Category Rotation: +2.5
TER: 0.07%
AUM: 3.95B
Avg Turnover: 21.9M
Risk 3d forecast
Volatility20.3%
VaR 5th Pctl3.48%
VaR vs Median-4.49%
Reward TTM
Sharpe Ratio1.39
Rel. Str. IBD84.3
Rel. Str. Peer Group50 pctl
Character TTM
Beta0.218
Beta Downside0.191
Hurst Exponent0.465
Choppyness54.9%
Drawdowns 3y
Max DD16.87%
CAGR/Max DD0.97
CAGR/Mean DD3.37

Warnings

No concerns identified

Tailwinds

Supp Ema8

Seasonality 11.7 years of data

Jan +0.1% 7
Feb -1.1% 19
Mar -1.3% 17
Apr +0.1% 2
May -0.0% 10
Jun +0.9% 19
Jul +0.9% 19
Aug +0.0% 5
Sep -1.6% 32
Oct -2.6% 12
Nov +4.8% 44
Dec -0.3% 13

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: FHLC Fidelity Health Care Index

The Fidelity MSCI Health Care Index ETF (FHLC) is a non-diversified exchange-traded fund listed on the NYSE that seeks to track the performance of the MSCI USA IMI Health Care 25/50 Index, representing the U.S. health care sector. The fund commits at least 80% of its assets to securities in its underlying benchmark, though it is not required to hold every constituent of that index.

The 25/50 designation in the index name refers to Internal Revenue Code diversification limits for regulated investment companies, capping the weight of any single issuer to help mitigate concentration risk. The broader U.S. health care sector encompasses pharmaceuticals, biotechnology, medical devices, health care providers, and managed care organizations, and is generally viewed as a defensive segment due to the relatively stable demand for medical products and services.

Launched in October 2013 and categorized within the Health ETF segment, FHLC is structured as a mid-cap fund, reflecting its orientation toward mid-sized companies within the sector.

Headlines to Watch Out For
  • Drug pricing regulation pressures pharmaceutical profit margins
  • Aging demographics drive sustained healthcare sector demand
  • Interest rate cuts boost high-multiple biotech valuations
What is the price of FHLC shares?

As of November 11, 2026, the stock is trading at USD 90.20 with a total of 316,318 shares traded. Over the past week, the price has changed by +2.43%, over one month by +8.87%, over three months by +10.48% and over the past year by +29.12%.

Current recommended Stop Loss: 88.20 (which is 2.2% or 1.2 ATR below the current price).

Is FHLC a buy, sell or hold?

Fidelity Health Care Index has no consensus analysts rating.